Skip to main content

Table 2 Market shares* of types of oral hypoglycemic agents by country (2002 to 2012)

From: Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand

  2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Brazil retail            
Alpha-glucosidase inhibitors 2.18 2.12 2.06 1.90 2.03 1.89 1.55 1.45 1.21 0.81 0.62
Biguanides 34.56 37.50 40.94 43.61 45.70 48.61 49.55 49.56 51.39 54.21 57.53
DPP4 inhibitors 0 0 0 0 0 0.77 2.25 2.70 2.48 2.43 2.77
Fixed dose combinations** 1.51 4.35 6.87 8.29 9.04 8.50 9.26 10.07 9.50 8.32 7.60
Non-sulfonylurea secretagogues 3.55 3.58 3.28 2.94 2.76 2.19 1.55 1.25 0.98 0.58 0.33
Thiazolidinediones 0.73 0.86 0.93 1.14 1.55 1.34 0.99 0.93 0.76 0.47 0.46
Sulfonylureas 57.48 51.60 45.93 42.12 38.92 36.70 34.85 34.04 33.68 33.19 30.69
China hospital            
Alpha-glucosidase inhibitors 10.50 13.48 16.65 18.41 19.76 21.06 21.95 23.16 25.48 26.94 27.35
Biguanides 45.41 43.48 39.27 38.03 37.34 36.57 35.68 34.31 32.93 33.22 34.64
DPP4 inhibitors 0 0 0 0 0 0 0 0 0.01 0.06 0.15
Fixed dose combinations** 0 0 0 0 0 0.01 0.03 0.15 0.21 0.13 0.15
Non-sulfonylurea secretagogues 2.26 3.85 5.58 6.98 8.31 10.33 12.05 13.72 14.72 15.16 14.13
Thiazolidinediones 0.37 0.66 0.93 1.26 2.35 2.99 3.31 3.79 3.82 3.30 2.79
Sulfonylureas 41.45 38.54 37.56 35.32 32.24 29.04 26.98 24.88 22.83 21.19 20.80
Thailand hospital            
Alpha-glucosidase inhibitors 1.37 1.12 1.01 1.02 1.17 1.27 1.29 1.34 1.29 1.16 1.09
Biguanides 41.79 45.92 48.30 49.27 50.45 52.09 54.78 55.11 55.26 55.00 56.63
DPP4inhibitors 0 0 0 0 0 0 0.08 0.23 0.41 0.62 0.71
Fixed dose combinations** 0 0 0.01 0.05 0.08 0.12 0.20 0.31 0.40 0.49 0.68
Non-sulfonylurea secretagogues 0.15 0.15 0.14 0.14 0.16 0.17 0.16 0.16 0.15 0.14 0.15
Thiazolidinediones 0.43 0.54 0.71 0.81 1.18 1.28 1.38 1.61 1.90 2.15 2.33
Sulfonylureas 56.26 52.27 49.83 48.71 46.96 45.06 42.11 41.25 40.58 40.45 38.41
Thailand retail            
Alpha-glucosidase inhibitors 1.83 1.58 1.30 1.11 1.98 1.92 1.69 1.73 2.28 1.86 2.75
Biguanides 35.12 32.10 37.81 42.00 42.82 43.16 39.94 43.41 39.71 41.17 40.81
DPP4 inhibitors 0 0 0 0 0 0 0 0 0.16 0.62 1.31
Fixed dose combinations** 0 0 0 0 0 0 0 0.09 0.06 0.05 0.27
Non-sulfonylurea secretagogues 0 0 0.19 0.22 0.38 0.41 0.47 0.50 0.50 0.43 0.50
Thiazolidinediones 0.23 0.50 0.54 0.62 0.66 0.58 0.54 1.43 1.75 1.74 2.37
Sulfonylureas 62.82 65.82 60.16 56.06 54.16 53.93 57.35 52.83 55.54 54.12 52.00
  1. *Market share is the percentage of the total market volume based on volume sold in standard units per 1000 population. IMS Health defines a standard unit as the smallest common dose of a product form: one tablet or capsule for oral formulations.
  2. **Fixed dose combinations include the following: cinnamomum loureirii & glipizide & metformin; glibenclamide & metformin; gliclazide & metformin; glimepiride & metformin; glimepiride & rosiglitazone; glipizide & metformin; metformin & nateglinide; metformin & pioglitazone; metformin & rosiglitazone; metformin & saxagliptin; metformin & sitagliptin; metformin & vildagliptin.
Back to article page

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us